1. Vaginal bleeding in gynecology Киндан кон кетиши. УАШнинг тактикаси.
Assistant department of obstetrics and gynecology GP TMA, MD
Yuldasheva Dilchehra Yusufhanovna

2. OBJECTIVES To understand the terminology of abnormal uterine bleeding.
 To review the etiology of abnormal uterine bleeding. 
To understand the basic investigation of abnormal uterine bleeding. 
To review the potential medical and surgical approaches in the treatment of abnormal uterine bleeding.

3. Кон кетиши ва хайз цикли бузилиши – 4%да УАШга мурожаат килишга сабаб булади.

4. Хайз кунларида нормада 30-40мл кон йукотилади Гиперполименорея – 80 мл
Асосий маълумотлар
20% тугиш ёшидаги аёллар куп хайз келишига шикоят киладилар, бирок уларнинг ярмида хайз циклининг бузилиши аникланади.
Хайз кунларида нормада 30-40мл кон йукотилади
Гиперполименорея – 80 мл

5. Normal Menstrual Cycle
 Menstration is a cyclic physiological phenomena starting at the age of Menarche (10-12years) till establishment of Menopause (45-55 yrs).
It is regulated by hypothalmo-pituitary- ovarian hormones secreted in pulsatile and cyclic pattern.

6. CHARACTERISTICS OF THE NORMAL MENSTRUAL CYCLE
 Flow lasts 2-7 days.
 Cycle days. 
Total menstrual blood loss < 80 ml.

7. Regulation of the menstrual cycle

8. ABNORMAL UTERINE BLEEDING (AUB)
An alteration in the volume, pattern, and or duration of menstrual blood flow.
 Most common reason for gynecologic referral  More than 10 million women in USA currently suffer from AUB.
 6 million seek medical help each year. 
AUB accounts for 15% of office visits and almost 25 % of gynecologic operations.

9. DYSFUNCTIONAL UTERINE BLEEDING (DUB)
 ABNORMAL uterine bleeding with no demonstrable organic, genital, or extragenital cause. 
Diagnosis of EXCLUSION  Patient presents with “abnormal uterine bleeding”
 Occurs most often shortly after menarche and at the end of the reproductive years (20% adolescents, 50% years) 
Most frequently due to anovulation

10. QUESTION 1:Which statement is TRUE?
(A)The normal menstrual cycle is 24 days with flow for 8 days with 90 ml of blood loss.
(B) Dysfunction uterine bleeding is most frequently due to ovulation.
(C) Abnormal uterine bleeding is the most common gynecololgic referral.
(D) Dysfunction uterine bleeding most often occurs for women ages

11. DEFINITIONS
 Menorrhagia (hypermenorrhea)  prolonged (>7days) and or excessive (>80ml) uterine bleeding occurring at REGULAR intervals
 Metrorrhagia  uterine bleeding occurring at completely irregular but frequent intervals, the amount being variable. 
Menometrorrhagia  uterine bleeding that is prolonged AND occurs at completely irregular intervals.

12. DEFINITIONS
 Polymenorrhea  uterine bleeding at regular intervals of < 21 days. 
Intermenstrual Bleeding  bleeding of variable amounts occurring between regular menstrual periods. 
Oligomenorrhea  uterine bleeding at regular intervals from 35 days to 6 months.  Amenorrhea  ABSENCE of uterine bleeding for > 6 months. 
Postmenopausal Bleeding  uterine bleeding that occurs more than 1 year after last menses in a woman with ovarian failure.

13. DIFFERENTIAL DIAGNOSIS OF AUB
Organic (reproductive tract disease, systemic disease and iatrogenic causes) 
Non-organic (DUB)

14. “YOU MUST EXCLUDE ALL ORGANIC CAUSES FIRST!”
Pregnancy related causes 
Medications
 Anatomic,  Infectious disease 
Endocrine abnormalities  Bleeding disorders
 Endometrial hyperplasia 
Neoplasm

15. Бачадондан дисфункционал кон кетиш (БДК)
Rapid Initial Assessment
Бачадондан дисфункционал кон кетиш (БДК)
БДК – жинсий аъзолардаги органик узгаришлар билан боглик булмаган кон кетиш булиб, гонадотроп ва тухумдон гормонларининг ишлаб чикилиши ва ритми билан боглик кон кетиши. Учраш сони – % (гинекологик касалликлар ичида)

16. Этиологияси Рухий омиллар Аклий ва жисмоний чарчаш
Rapid Initial Assessment
Этиологияси
Рухий омиллар
Аклий ва жисмоний чарчаш
Уткир ва сурункали инфекция
Бачадон ортиклари яллигланиши
Бошка безлар фаолиятининг бузилиши
Етарли овкатланмаслик ва витаминлар етишмаслиги

17. Патогенези Фолликула ривожланиш жараёни бузилади
Rapid Initial Assessment
Патогенези
Фолликула ривожланиш жараёни бузилади
Организмга узок вакт эстрогенлар таъсир килади
Овуляция бузилади
Сарик тана булмайди

18. БДК хар хил ёшда учрайди
Rapid Initial Assessment
БДК хар хил ёшда учрайди
Ювенил – жинсий етилиш даврида 20 ёшгача – %
Жинсий етилган даврда – ёшда %
Климактерик даврда – 40 ёшдан менопаузагача – %

19. Ановулятор БДКда фолликулалар етилиши 2 хил куринишда бузилади
Rapid Initial Assessment
Ановулятор БДКда фолликулалар етилиши 2 хил куринишда бузилади
Фолликулалар персиситенцияси
Фолликулалар атрезияси

20. Клиникаси Персистенция: хайз 1-2 хафтадан 8 хафтагача кеч колади
хайз 1-2 хафтадан 8 хафтагача кеч колади
Куп имкдорда кон кетади
Киска вакт кон кетади
Атрезия:
Хайз 3-4 хафтага кеч колади
Кам микдорда кон кетади
Узок вакт давом этади (1-2 ой)

21. AUB RELATED TO AGE  Prior to Menarche  Reproductive Age 
Postmenopausal

22. AUB—Reproductive Age 
Pregnancy and pregnancy related complications
 Medications and other iatrogenic causes 
Systemic conditions 
Genital tract pathology

23. Pregnancy Related AUB
Spontaneous abortion

24. Pregnancy Related AUB Ectopic pregnancy

25. Pregnancy Related AUB
Placenta previa

26. Pregnancy Related AUB
Placental abruption
Placental abruption

27. Pregnancy Related AUB Gestational Trophoblastic Disease

28. Puerperal complications
Pregnancy Related AUB
Puerperal complications

29. Iatrogenic Causes  Medications
Anticoagulants, Antipsychotics, Corticosteroids, Hormonal medications, IUD, Tamoxifen

30. Medications Warfarin—bleeding complications usually o
Contraceptive Bleeding  OCPs (lower dose, skipped pills, altered absorption/metabolism) (39% starting OCPs will have irregular bleeding—midcycle within first 3 months) 
Depo Provera (50% irregular bleeding after 1 st dose, 25 % after 1 year  biggest reason for discontinuation) ccur when INR exceeds therapeutic range

31. Systemic Causes Thyroid disease  Polycystic ovary disease 
Coagulopathies 
Hepatic disease
 Adrenal hyperplasia and Cushings 
Pituitary adenoma or hyperprolactinemia 
Hypothalamic suppression (from stress, weight loss, excessive exercise )

32. Endocrine Abnormalities 
Hypothyroidism
 PCOS  (Polycystic Ovary Syndrome)
Cushing’s syndrome
 CAH (Congenital adrenal hyperplasia)

33. Bleeding Disorders
Willebrand’s disease and Thrombocytopenia

34. Genital Tract Pathology
 Infections—cervicitis, endometritis, salpingitis 
Trauma—foreign body, abrasions, lacerations

35. Genital Tract Pathology
Neoplastic  Benign— adenomyosis, leiomyoma, polyps of cervix or endometrium

36. Genital Tract Pathology
 Premalignant—cervical dysplasia, endometrial hyperplasia
Malignant—cervical, endometrial, ovarian, leiomyosarcoma

37. Genital Tract Pathology
Fibroids  Often asymptomatic  Risk factors  nulliparity, obesity, family history, hypertension, African-American 
Usually causes heavier or prolonged menses  Treatment options—expectant, medical, embolization, ablation, surgery

38. Genital Tract Pathology
Polyps  Endometrial (intermenstrual bleeding, irregular bleeding, menorrhagia) 
Cervical (intermenstrual bleeding, postcoital spotting)

39. Genital Tract Pathology
Postcoital Bleeding 
Women age 20-40
25% cervical eversion 
Endocervical polyps, cervicitis (Chlamydia) 
Dysplasia/cancer 
Vaginal atrophy 
Unexplained = Colposcopy

40. Genital Tract Pathology
Premalignant—Endometrial Hyperplasia  Overgrowth of glandular epithelium of the endometrial lining.  Usually occurs when a patient is exposed to unopposed estrogen (either estrogenically or because of anovulation)  Rate of neoplasm (simple to complex, 1 to 30%)

41. Genital Tract Pathology
Premalignant—Endometrial Hyperplasia 
Simple—often regresses spontaneously, progestin treatment used for treating bleeding may help in treating hyperplasia as well 
Complex with atypia—1 study found incidence of concomitant endometrial cancer in 40% of cases

42. Genital Tract Pathology—Malignant
Uterine Cancer  4 th most common cancer in women  Risk factors (nulliparity, late menopause [after age 52], obesity, diabetes, unopposed estrogen therapy, tamoxifen, history of atypical endometrial hyperplasia)  Most often presents as postmenopausal bleeding in the sixth and seventh decade (only 10% of patients with PMB will have endometrial cancer) 

43. General Principles of Evaluation for AUB
Pregnancy test

44. General Principles of Evaluation for AUB
Pap, cultures for STDs

45. General Principles of Evaluation for AUB
Screen for vWD when appropriate -
A von Willebrand factor (vWF) antigen test

46. Ташхислаш Персистенция Атрезия Базал харорат монофазали
«Корачик» симптоми ++ +
«Папоротник» симптоми
+++
+; ++
Шиллик чузилиши
10-12 см
3-4 см
Эндометрий гистологияси
Гиперплазия, мутлак гиперэстрогения
Безли-кистоз гиперплазия, нисбий гиперэстрогения
Rapid Initial Assessment

47. Transvaginal Ultrasound
Evaluation of AUB
Transvaginal Ultrasound

48. General Principles of Evaluation for AUB
Endometrial Biopsy (Unsatisfacto ry if it is a focal lesion)

49. Evaluation of AUB
Endometrial Biopsy

50. AUB TREATMENT: Medical Management before Surgical 
Effective Methods include: estrogen, progesterone, or both NSAIDS Antifibrinolytic Agents Danazol GnRH agonists

51. AUB TREATMENT: Other Medical Therapy Options
Progestins 
 Medroxyprogesterone
 Norethindrone (Aygestin)
Norethindrone (Micronor)
Micronized Progesterone (Prometrium)
 IUD (Levonorgestrel [Mirena]) 

52. AUB TREATMENT: Surgical Options
 Operative Hysteroscopy 
Myomectomy (Hysteroscopic, Laparoscopic, Open) 
Uterine Fibroid Embolization (UFE) 
Hysterectomy

53. AUB TREATMENT: Surgical Options
Operative Hysteroscopy

54. AUB TREATMENT: Surgical Options
Endometrial Ablation

55. AUB TREATMENT: Surgical Options
Uterine Fibroid Embolization (UFE)

56. Summary:
 Differential diagnosis depends on patient’s age  ALWAYS exclude pregnancy  Adolescent females (most likely anovulatory but exclude STDs and vWD) 

57. Summary:
Reproductive Age females (if anovulatory exclude cancer/precancer if >35 but most likely PCOS)  Reproductive Age females (if ovulatory exclude organic causes such as fibroid or polyps but most likely idiopathic)

58. Summary:
 Perimenopausal/Postmenopausal (always exclude cancer but usually is not cancer)  Consider risks for endometrial cancer (nulliparity, late menopause [after age 52], obesity, diabetes, unopposed estrogen therapy, tamoxifen, and history of atypical endometrial hyperplasia)  Whether reality or perception, heavy bleeding disrupts a women’s quality of life.

59. THANK YOU FOR ATTENTION